DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
185:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
6. BIOLOGICALS:@0.084848:0.079411:0.265941:0.079411:0.265941:0.059814:0.084848:0.059814:0.013170:0.006585:0.006585:0.013641:0.006585:0.019756:0.010348:0.019756:0.019756:0.006585:0.018344:0.017404:0.010348:0.012230
Signal transduction  or  biochemical com-:@0.084848:0.097179:0.475767:0.097179:0.475767:0.081423:0.084848:0.081423:0.009583:0.003848:0.012950:0.011738:0.013143:0.003848:0.008409:0.006523:0.005792:0.013143:0.011738:0.007466:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003065:0.012604:0.005792:0.005330:0.003063:0.013123:0.003848:0.012604:0.012450:0.011738:0.012508:0.018049:0.003848:0.012450:0.013143:0.003848:0.008409:0.012450:0.012604:0.018049:0.006388
munication  in  the  cell plays an  essential :@0.084848:0.112657:0.481084:0.112657:0.481084:0.096901:0.084848:0.096901:0.018049:0.011699:0.011738:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.003735:0.003848:0.011738:0.005330:0.003741:0.006523:0.011738:0.012508:0.005330:0.003733:0.012450:0.012508:0.003848:0.003848:0.009082:0.013123:0.003848:0.013143:0.010314:0.007466:0.009082:0.013143:0.011738:0.005330:0.003739:0.012508:0.007466:0.007466:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.005330
role in the normal cell cycle and cell divi-:@0.084848:0.128135:0.475758:0.128135:0.475758:0.112379:0.084848:0.112379:0.005713:0.012604:0.003848:0.012508:0.006408:0.003848:0.011738:0.006408:0.006523:0.011738:0.012508:0.006408:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.006408:0.012450:0.012508:0.003848:0.003848:0.006408:0.012450:0.010314:0.012450:0.003848:0.012508:0.006408:0.013143:0.011738:0.013181:0.006408:0.012450:0.012508:0.003848:0.003848:0.006408:0.013181:0.003848:0.010660:0.003902:0.006388
sion.  Binding of a ligand such as a growth :@0.084848:0.143613:0.481084:0.143603:0.481084:0.127847:0.084848:0.127857:0.007466:0.003848:0.012604:0.011738:0.005330:0.012432:0.004503:0.011045:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.004503:0.012604:0.006042:0.004503:0.013143:0.004503:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.004503:0.007466:0.011699:0.012450:0.011738:0.004503:0.013143:0.007466:0.004503:0.013143:0.004503:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.792831
26:@0.125833:0.137984:0.138262:0.137984:0.138262:0.128799:0.125833:0.128799:0.006215:0.006215
factor to its cell-surface receptor (usually a :@0.084850:0.159081:0.481084:0.159081:0.481084:0.143326:0.084850:0.143326:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.004137:0.006523:0.012604:0.004137:0.003848:0.006523:0.007466:0.004137:0.012450:0.012508:0.003848:0.003848:0.006388:0.007466:0.011699:0.006712:0.006042:0.013143:0.012450:0.012508:0.004137:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.004137:0.007100:0.011699:0.007466:0.011699:0.013143:0.003848:0.003848:0.010314:0.004156:0.013143:0.005330
tyrosine kinase) leads to activation of the :@0.084850:0.174560:0.481087:0.174560:0.481087:0.158804:0.084850:0.158804:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.006927:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007100:0.006927:0.003848:0.012508:0.013143:0.013181:0.007466:0.006927:0.006523:0.012604:0.006927:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.006927:0.012604:0.006042:0.006927:0.006523:0.011738:0.012508:0.005330
receptor.  Activation of  a receptor  in-:@0.084850:0.190038:0.475768:0.190028:0.475768:0.174272:0.084850:0.174282:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.004370:0.005330:0.012430:0.012565:0.014239:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.012565:0.012604:0.006042:0.005330:0.007226:0.013143:0.012565:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.007218:0.003848:0.011738:0.731678
26:@0.169974:0.184409:0.182403:0.184409:0.182403:0.175223:0.169974:0.175223:0.006215:0.006215
volves  the transfer of a large phosphate :@0.084849:0.205506:0.481100:0.205506:0.481100:0.189750:0.084849:0.189750:0.010660:0.012604:0.003848:0.010660:0.012508:0.007466:0.005330:0.003244:0.006523:0.011738:0.012508:0.008563:0.006523:0.005792:0.013143:0.011738:0.007466:0.006042:0.012508:0.005792:0.008563:0.012604:0.006042:0.008563:0.013143:0.008563:0.003848:0.013143:0.005811:0.012950:0.012508:0.008563:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006523:0.012508:0.005330
group from adenosine triphosphate (ATP) :@0.084849:0.220984:0.481096:0.220984:0.481096:0.205228:0.084849:0.205228:0.012950:0.005709:0.012604:0.011699:0.013123:0.007274:0.006042:0.005713:0.012604:0.018049:0.007274:0.013143:0.013181:0.012508:0.011738:0.012604:0.007466:0.003848:0.011738:0.012508:0.007274:0.006523:0.005792:0.003848:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006523:0.012508:0.007274:0.007100:0.012677:0.008197:0.011392:0.007100:0.005330
via a kinase to a protein such as tyrosine :@0.084849:0.236462:0.481129:0.236462:0.481129:0.220706:0.084849:0.220706:0.010660:0.003848:0.013143:0.007351:0.013143:0.007351:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007351:0.006523:0.012604:0.007351:0.013143:0.007351:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.007335:0.007466:0.011699:0.012450:0.011738:0.007351:0.013143:0.007466:0.007351:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.005330
which activates a cascade of events.  :@0.084849:0.251649:0.481087:0.251634:0.481087:0.235878:0.084849:0.235894:0.015990:0.011738:0.003848:0.012450:0.011738:0.010718:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.012508:0.007466:0.010718:0.013143:0.010718:0.012450:0.013143:0.007466:0.012450:0.013143:0.013181:0.012508:0.010718:0.012604:0.006042:0.010718:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.012430:0.635693
26:@0.463323:0.246015:0.475753:0.246015:0.475753:0.236829:0.463323:0.236829:0.006215:0.006215
These events may entitle the switching on :@0.084848:0.266821:0.481108:0.266821:0.481108:0.251065:0.084848:0.251065:0.008197:0.011738:0.012508:0.007466:0.012508:0.006067:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.006081:0.018049:0.013143:0.010314:0.006081:0.012508:0.011738:0.006523:0.003848:0.006523:0.003848:0.012508:0.006071:0.006523:0.011738:0.012508:0.006067:0.007466:0.015990:0.003848:0.006523:0.012450:0.011738:0.003848:0.011738:0.012950:0.006081:0.012604:0.011738:0.005330
or off of a particular process.:@0.084848:0.282008:0.352421:0.282008:0.352421:0.266252:0.084848:0.266252:0.012604:0.005792:0.005330:0.012604:0.006083:0.006042:0.005330:0.012604:0.006042:0.005330:0.013143:0.005330:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330:0.013123:0.005702:0.012604:0.012450:0.012508:0.007466:0.007466:0.005330
26:@0.352419:0.276376:0.364849:0.276376:0.364849:0.267191:0.352419:0.267191:0.006215:0.006215
Growth  factors  stimulate proliferation, :@0.103030:0.297176:0.481105:0.297176:0.481105:0.281420:0.103030:0.281420:0.016779:0.005713:0.012604:0.015990:0.006523:0.011738:0.005330:0.007697:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.007699:0.007466:0.006523:0.003848:0.018049:0.011699:0.003848:0.013143:0.006523:0.012508:0.013046:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
differentiation, interaction with other cells, :@0.084846:0.312363:0.481082:0.312363:0.481082:0.296607:0.084846:0.296607:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005569:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005567:0.015990:0.003848:0.006523:0.011738:0.005580:0.012604:0.006523:0.011738:0.012508:0.005792:0.005565:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.005330
and growth and survival in cells.  In can-:@0.084846:0.327550:0.475768:0.327538:0.475768:0.311782:0.084846:0.311794:0.013143:0.011738:0.013181:0.006985:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.006973:0.013143:0.011738:0.013181:0.006985:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006985:0.003848:0.011738:0.006985:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.012441:0.006985:0.004349:0.011738:0.006985:0.012450:0.013143:0.011738:0.531664
39:@0.389558:0.321919:0.401988:0.321919:0.401988:0.312733:0.389558:0.312733:0.006215:0.006215
cer  cells, growth  factors  are involved in :@0.084839:0.342725:0.481090:0.342725:0.481090:0.326969:0.084839:0.326969:0.012450:0.012508:0.005792:0.005330:0.004528:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.009871:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330:0.004528:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.004528:0.013143:0.005715:0.012508:0.009871:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.009871:0.003848:0.011738:0.005330
invasion, metastasis  and angiogenesis as :@0.084839:0.357912:0.481073:0.357912:0.481073:0.342156:0.084839:0.342156:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.012604:0.011738:0.005330:0.008236:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.003848:0.007466:0.005330:0.002919:0.013143:0.011738:0.013181:0.008236:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.007466:0.003848:0.007466:0.008236:0.013143:0.007466:0.005330
they activate an altered, mutated signal-:@0.084839:0.373099:0.475750:0.373099:0.475750:0.357343:0.084839:0.357343:0.006523:0.011738:0.012508:0.010314:0.006473:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.012508:0.006485:0.013143:0.011738:0.006485:0.013143:0.003848:0.006523:0.012508:0.005715:0.012508:0.013181:0.005330:0.006473:0.018049:0.011699:0.006523:0.013143:0.006523:0.012508:0.013181:0.006471:0.007466:0.003848:0.012950:0.011738:0.013143:0.003848:0.006388
ling process.:@0.084839:0.388286:0.199216:0.388286:0.199216:0.372530:0.084839:0.372530:0.003848:0.003848:0.011738:0.012950:0.005330:0.013123:0.005715:0.012604:0.012450:0.012508:0.007466:0.007466:0.005330
26, 39:@0.199222:0.382643:0.230297:0.382643:0.230297:0.373457:0.199222:0.373457:0.006215:0.006215:0.003107:0.003107:0.006215:0.006215
 :@0.230303:0.388262:0.235633:0.388262:0.235633:0.372506:0.230303:0.372506:0.005330
Certain  biological chemotherapeutics :@0.103033:0.403449:0.481093:0.403449:0.481093:0.387693:0.103033:0.387693:0.015644:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.005330:0.007968:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.013316:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012490:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.007466:0.005330
such as monoclonal antibodies (MAbs) :@0.084849:0.418636:0.481098:0.418636:0.481098:0.402880:0.084849:0.402880:0.007466:0.011699:0.012450:0.011738:0.012411:0.013143:0.007466:0.012411:0.018049:0.012604:0.011738:0.012594:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.012411:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.003848:0.012508:0.007466:0.012411:0.007100:0.017684:0.014239:0.013123:0.007466:0.007100:0.005330
and small-molecular-weight agents are :@0.084849:0.433823:0.481100:0.433823:0.481100:0.418067:0.084849:0.418067:0.013143:0.011738:0.013181:0.013508:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.018049:0.012604:0.003862:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.006388:0.015990:0.012508:0.003848:0.012950:0.011738:0.006523:0.013508:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.013508:0.013143:0.005713:0.012508:0.005330
targeted at cell-surface- and intracellular :@0.084849:0.449010:0.481085:0.449010:0.481085:0.433254:0.084849:0.433254:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.006600:0.013143:0.006523:0.006600:0.012450:0.012508:0.003848:0.003848:0.006388:0.007466:0.011699:0.006718:0.006042:0.013143:0.012450:0.012508:0.006388:0.006600:0.013143:0.011738:0.013181:0.006600:0.003848:0.011738:0.006523:0.005792:0.013143:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005330
receptors of the tyrosine kinase family.:@0.084849:0.464197:0.439221:0.464197:0.439221:0.448441:0.084849:0.448441:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007466:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.010314:0.005682:0.012604:0.007466:0.003848:0.011738:0.012508:0.005330:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330:0.006042:0.013143:0.018049:0.003848:0.003848:0.010314:0.005330
1,26:@0.439226:0.458547:0.460978:0.458547:0.460978:0.449361:0.439226:0.449361:0.006215:0.003107:0.006215:0.006215
Specific growth-factor targets include epi-:@0.103030:0.479347:0.475777:0.479347:0.475777:0.463591:0.103030:0.463591:0.009063:0.012604:0.011988:0.011930:0.003329:0.004426:0.004426:0.011930:0.005028:0.012431:0.005192:0.012084:0.015471:0.006004:0.011218:0.005869:0.005523:0.012623:0.011930:0.006004:0.012084:0.005272:0.005030:0.006004:0.012623:0.005288:0.012431:0.011988:0.006004:0.006947:0.005030:0.003329:0.011218:0.011930:0.003329:0.011180:0.012662:0.011988:0.005030:0.011988:0.012604:0.003329:0.006388
dermal growth factor (EGF) and its receptors :@0.084846:0.494534:0.481122:0.494534:0.481122:0.478778:0.084846:0.478778:0.012662:0.011988:0.005802:0.017530:0.012623:0.003329:0.004310:0.012431:0.005194:0.012084:0.015471:0.006004:0.011218:0.004310:0.005523:0.012623:0.011930:0.006004:0.012084:0.005272:0.004301:0.006581:0.009794:0.016260:0.008813:0.006581:0.004310:0.012623:0.011218:0.012662:0.004301:0.003329:0.006004:0.006947:0.004301:0.005194:0.011988:0.011930:0.011988:0.012604:0.006004:0.012084:0.005272:0.007468:0.005330
(EGFRs), and vascular endothelial growth :@0.084846:0.509721:0.481082:0.509721:0.481082:0.493965:0.084846:0.493965:0.006581:0.009794:0.016260:0.008813:0.011161:0.006947:0.006581:0.004811:0.011680:0.012623:0.011218:0.012662:0.011680:0.010141:0.012623:0.006947:0.011930:0.011180:0.003329:0.012623:0.005272:0.011680:0.011988:0.011218:0.012662:0.012084:0.006004:0.011218:0.011988:0.003329:0.003329:0.012623:0.003329:0.011680:0.012431:0.005194:0.012084:0.015471:0.006004:0.011736:0.005330
factor (VEGF) and its receptors (VEGFRs).  :@0.084846:0.524908:0.461535:0.524890:0.461535:0.509134:0.084846:0.509152:0.005523:0.012623:0.011930:0.006004:0.012084:0.005272:0.004811:0.006581:0.012989:0.009794:0.016260:0.008813:0.006581:0.004811:0.012623:0.011218:0.012662:0.004811:0.003329:0.006004:0.006947:0.004811:0.005194:0.011988:0.011930:0.011988:0.012604:0.006004:0.012084:0.005272:0.006947:0.004811:0.006581:0.012989:0.009794:0.016260:0.008813:0.011161:0.006947:0.006581:0.005330:0.011604:0.257782
39:@0.444073:0.519271:0.456200:0.519271:0.456200:0.510085:0.444073:0.510085:0.005912:0.006215
Aflibercept  acts  as  a  soluble  receptor :@0.103029:0.540077:0.481089:0.540077:0.481089:0.524321:0.103029:0.524321:0.013716:0.004666:0.004143:0.003333:0.012606:0.011986:0.005138:0.011928:0.011988:0.012606:0.006002:0.005330:0.005245:0.013143:0.012450:0.006523:0.007466:0.005330:0.005765:0.013143:0.007466:0.005330:0.005773:0.013143:0.005330:0.005769:0.007466:0.012604:0.003848:0.011699:0.013123:0.003848:0.012508:0.005330:0.005767:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330
that  binds to  human  VEGF-A, to  human :@0.084845:0.555264:0.481096:0.555264:0.481096:0.539508:0.084845:0.539508:0.006523:0.011738:0.013143:0.006523:0.005330:0.004126:0.013123:0.003848:0.011738:0.013181:0.007466:0.009467:0.006523:0.012604:0.005330:0.004124:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330:0.004127:0.013508:0.010314:0.016779:0.009333:0.006388:0.014239:0.005330:0.009467:0.006523:0.012604:0.005330:0.004126:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330
VEGF-B and to human PlGF. By binding to :@0.084845:0.570451:0.481083:0.570451:0.481083:0.554695:0.084845:0.554695:0.013508:0.010314:0.016779:0.009333:0.006388:0.011045:0.006273:0.013143:0.011738:0.013181:0.006273:0.006523:0.012604:0.006273:0.011738:0.011699:0.018049:0.013143:0.011738:0.006273:0.011392:0.003848:0.016779:0.007810:0.005330:0.006273:0.011045:0.010314:0.006273:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.006273:0.006523:0.012604:0.005330
these  endogenous  ligands,  aflibercept :@0.084845:0.585638:0.481087:0.585638:0.481087:0.569882:0.084845:0.569882:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.010487:0.012508:0.011738:0.013181:0.012604:0.012950:0.012496:0.011738:0.012604:0.011699:0.007466:0.005330:0.010487:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330:0.005330:0.010499:0.013143:0.004666:0.004666:0.003848:0.013123:0.012508:0.005659:0.012450:0.012508:0.013123:0.006523:0.005330
can inhibit the binding and activation of :@0.084845:0.600825:0.481085:0.600825:0.481085:0.585069:0.084845:0.585069:0.012450:0.013143:0.011738:0.007755:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007755:0.006523:0.011738:0.012508:0.007755:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.007755:0.013143:0.011738:0.013181:0.007755:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.007755:0.012604:0.006042:0.005330
their receptors. This inhibition can result in :@0.084845:0.616012:0.481085:0.616012:0.481085:0.600256:0.084845:0.600256:0.006523:0.011738:0.012508:0.003848:0.005792:0.006945:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007466:0.005330:0.006943:0.008197:0.011738:0.003848:0.007466:0.006954:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.006954:0.012450:0.013143:0.011738:0.006952:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.006954:0.003848:0.011738:0.005330
decreased neovascularisation  and de-:@0.084845:0.631199:0.475745:0.631199:0.475745:0.615443:0.084845:0.615443:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.014624:0.011738:0.012508:0.012604:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.009308:0.013143:0.011738:0.013181:0.014624:0.013181:0.012508:0.006388
creased vascular permeability. Aflibercept :@0.084845:0.646386:0.481079:0.646386:0.481079:0.630630:0.084845:0.630630:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.004868:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.004866:0.013123:0.012508:0.006325:0.018049:0.012508:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010327:0.005330:0.004863:0.013714:0.004666:0.004145:0.003333:0.012606:0.011986:0.005138:0.011930:0.011986:0.012606:0.006523:0.005330
is used in combination with 5-fluorouracil, :@0.084845:0.661573:0.481089:0.661573:0.481089:0.645817:0.084845:0.645817:0.003333:0.006950:0.007566:0.011178:0.006950:0.011986:0.012663:0.007566:0.003848:0.011738:0.008090:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.008086:0.015990:0.003848:0.006523:0.011738:0.008086:0.010660:0.006388:0.004666:0.004666:0.011699:0.012604:0.005705:0.012604:0.011699:0.005792:0.013143:0.012450:0.003848:0.003848:0.005330:0.005330
leucovorin and irinotecan-(FOLFIRI), and is :@0.084845:0.676760:0.481081:0.676760:0.481081:0.661005:0.084845:0.661005:0.003848:0.012508:0.011699:0.012450:0.012604:0.010660:0.012604:0.005792:0.003848:0.011738:0.005232:0.013143:0.011738:0.013181:0.005240:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.006388:0.007100:0.009333:0.016722:0.008890:0.009333:0.004349:0.011680:0.004349:0.007100:0.005330:0.005238:0.013143:0.011738:0.013181:0.005242:0.003848:0.007466:0.005330
indicated for patients with metastatic :@0.084845:0.691948:0.481066:0.691948:0.481066:0.676192:0.084845:0.676192:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.015721:0.006042:0.012604:0.005792:0.015721:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.015721:0.015990:0.003848:0.006523:0.011738:0.015721:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
colorectal cancer (mCRC) that is resistant :@0.084845:0.707135:0.481100:0.707135:0.481100:0.691379:0.084845:0.691379:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005561:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005544:0.007100:0.018049:0.015644:0.011680:0.015644:0.007100:0.005561:0.006523:0.011738:0.013143:0.006523:0.005546:0.003848:0.007466:0.005561:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.005330
to or has progressed following an oxalipl-:@0.084845:0.722322:0.475755:0.722322:0.475755:0.706566:0.084845:0.706566:0.006523:0.012604:0.007235:0.012604:0.005792:0.007235:0.011738:0.013143:0.007466:0.007235:0.013123:0.005717:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.007235:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.007235:0.013143:0.011738:0.007235:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003856:0.006388
atin-containing regimen.:@0.084845:0.737509:0.315029:0.737509:0.315029:0.721753:0.084845:0.721753:0.013143:0.006523:0.003848:0.011738:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.005702:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330
119:@0.315024:0.731803:0.333669:0.731803:0.333669:0.722618:0.315024:0.722618:0.006215:0.006215:0.006215
EGF belongs to the human epidermal re-:@0.103030:0.752603:0.475784:0.752603:0.475784:0.736847:0.103030:0.736847:0.010102:0.016568:0.009121:0.005205:0.012912:0.012296:0.003637:0.012392:0.011526:0.012738:0.007254:0.005215:0.006312:0.012392:0.005205:0.006312:0.011526:0.012296:0.005205:0.011526:0.011488:0.017838:0.012931:0.011526:0.005215:0.012296:0.012912:0.003637:0.012969:0.012296:0.006111:0.017838:0.012931:0.003637:0.005205:0.005501:0.012296:0.006388
ceptor (HER) tyrosine kinase family that is :@0.084846:0.767790:0.481105:0.767790:0.481105:0.752034:0.084846:0.752034:0.012238:0.012296:0.012912:0.006312:0.012392:0.005580:0.008775:0.006889:0.012931:0.010102:0.011468:0.006889:0.008775:0.006312:0.010102:0.005499:0.012392:0.007254:0.003637:0.011526:0.012296:0.008775:0.009448:0.003637:0.011526:0.012931:0.007254:0.012296:0.008775:0.005830:0.012931:0.017838:0.003637:0.003637:0.010102:0.008775:0.006312:0.011526:0.012931:0.006312:0.008775:0.003637:0.007470:0.005330
responsible  for  cell  proliferation,  growth :@0.084846:0.782977:0.481095:0.782977:0.481095:0.767221:0.084846:0.767221:0.005501:0.012296:0.007254:0.012912:0.012392:0.011526:0.007254:0.003637:0.012912:0.003637:0.012296:0.005330:0.008553:0.005830:0.012392:0.005580:0.005330:0.008553:0.012238:0.012296:0.003637:0.003637:0.005330:0.008553:0.012912:0.005501:0.012392:0.003637:0.003637:0.005830:0.012296:0.005580:0.012931:0.006312:0.003637:0.012392:0.011526:0.005118:0.005330:0.008553:0.012738:0.005501:0.012392:0.015779:0.006312:0.011734:0.005330
and survival, whereas VEGF induces en-:@0.084846:0.798164:0.475754:0.798164:0.475754:0.782408:0.084846:0.782408:0.012931:0.011526:0.012969:0.010930:0.007254:0.011488:0.005580:0.010449:0.003637:0.010449:0.012931:0.003637:0.005118:0.010930:0.015779:0.011526:0.012296:0.005501:0.012296:0.012931:0.007254:0.010930:0.013297:0.010102:0.016568:0.009121:0.010930:0.003637:0.011526:0.012969:0.011488:0.012238:0.012296:0.007254:0.010930:0.012296:0.011526:0.006388
dothelial cell proliferation and new blood-:@0.084846:0.813351:0.475773:0.813351:0.475773:0.797596:0.084846:0.797596:0.012969:0.012392:0.006312:0.011526:0.012296:0.003637:0.003637:0.012931:0.003637:0.006696:0.012238:0.012296:0.003637:0.003637:0.006696:0.012912:0.005501:0.012392:0.003637:0.003637:0.005830:0.012296:0.005580:0.012931:0.006312:0.003637:0.012392:0.011526:0.006696:0.012931:0.011526:0.012969:0.006696:0.011526:0.012296:0.015779:0.006696:0.012912:0.003637:0.012392:0.012392:0.012969:0.006388
vessel formation in the growing tumour.:@0.084846:0.828539:0.441215:0.828539:0.441215:0.812783:0.084846:0.812783:0.010449:0.012296:0.007254:0.007254:0.012296:0.003637:0.005118:0.005830:0.012392:0.006111:0.017838:0.012931:0.006312:0.003637:0.012392:0.011526:0.005118:0.003637:0.011526:0.005118:0.006312:0.011526:0.012296:0.005118:0.012738:0.005501:0.012392:0.015779:0.003637:0.011526:0.012738:0.005118:0.006312:0.011488:0.017838:0.012392:0.011488:0.004166:0.005330
26,39:@0.440968:0.822889:0.468442:0.822889:0.468442:0.813703:0.440968:0.813703:0.006092:0.006092:0.002984:0.006092:0.006215
Not  all biological chemotherapeutics :@0.103030:0.843688:0.481086:0.843688:0.481086:0.827933:0.103030:0.827933:0.014239:0.012604:0.006523:0.005330:0.008522:0.013143:0.003848:0.003848:0.013874:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.013874:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012490:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.007466:0.005330
target tyrosine kinases as some known as :@0.084846:0.858876:0.481095:0.858876:0.481095:0.843120:0.084846:0.843120:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.007218:0.006523:0.010314:0.005715:0.012604:0.007466:0.003848:0.011738:0.012508:0.007224:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007466:0.007235:0.013143:0.007466:0.007235:0.007466:0.012604:0.018049:0.012508:0.007222:0.009660:0.011738:0.012604:0.015990:0.011738:0.007216:0.013143:0.007466:0.005330
immunomodulating agents are often used :@0.084846:0.874354:0.481095:0.874354:0.481095:0.858598:0.084846:0.858598:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.018049:0.012604:0.013181:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.004349:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.004349:0.013143:0.005715:0.012508:0.004349:0.012604:0.006042:0.006523:0.012508:0.011738:0.004339:0.011699:0.007466:0.012508:0.013181:0.005330
to boost the ability of the immune system :@0.084846:0.889832:0.481080:0.889832:0.481080:0.874076:0.084846:0.874076:0.006523:0.012604:0.006625:0.013123:0.012604:0.012604:0.007466:0.006523:0.006627:0.006523:0.011738:0.012508:0.006625:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006639:0.012604:0.006042:0.006627:0.006523:0.011738:0.012508:0.006625:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006639:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.005330
to  fight  cancer.  Immunomodulating :@0.084846:0.905310:0.481104:0.905294:0.481104:0.889538:0.084846:0.889554:0.006523:0.012604:0.005330:0.015573:0.004686:0.004686:0.012950:0.011738:0.006523:0.005330:0.015577:0.012450:0.013143:0.011738:0.012450:0.012508:0.004376:0.005330:0.012426:0.020916:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.018049:0.012604:0.013181:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:-0.315102
26:@0.258350:0.899675:0.270780:0.899675:0.270780:0.890489:0.258350:0.890489:0.006215:0.006215
agents include certain MAbs, interferons :@0.084845:0.920772:0.481108:0.920772:0.481108:0.905016:0.084845:0.905016:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.009025:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.009025:0.012450:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.009025:0.017684:0.014239:0.013123:0.007466:0.005330:0.009025:0.003848:0.011738:0.006523:0.012508:0.006706:0.006042:0.012508:0.005709:0.012604:0.011738:0.007466:0.005330
and interleukins.:@0.084845:0.936250:0.234744:0.936250:0.234744:0.920494:0.084845:0.920494:0.013143:0.011738:0.013181:0.005330:0.003848:0.011738:0.006523:0.012508:0.005792:0.003848:0.012508:0.011699:0.009660:0.003848:0.011738:0.007466:0.005330
4,26:@0.234738:0.930625:0.256490:0.930625:0.256490:0.921439:0.234738:0.921439:0.006215:0.003107:0.006215:0.006215
Regorafenib  is a small  molecule inhibitor :@0.524242:0.079499:0.920481:0.079499:0.920481:0.063743:0.524242:0.063743:0.011680:0.012508:0.012950:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330:0.003375:0.003848:0.007466:0.008717:0.013143:0.008717:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330:0.003398:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.008717:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.005330
of  multiple membrane-bound and intra-:@0.524242:0.094990:0.915169:0.094990:0.915169:0.079234:0.524242:0.079234:0.012604:0.006042:0.005330:0.004587:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.009929:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.006388:0.013123:0.012604:0.011699:0.011738:0.013171:0.009929:0.013143:0.011738:0.013181:0.009929:0.003848:0.011738:0.006523:0.005792:0.013143:0.006388
cellular kinases involved in normal cellular :@0.524242:0.110482:0.920483:0.110482:0.920483:0.094726:0.524242:0.094726:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.006100:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007466:0.006088:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.006100:0.003848:0.011738:0.006090:0.011738:0.012604:0.006315:0.018049:0.013143:0.003848:0.006100:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005330
functions  and in pathologic processes :@0.524242:0.125973:0.920489:0.125973:0.920489:0.110217:0.524242:0.110217:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.009417:0.013143:0.011738:0.013181:0.014759:0.003848:0.011738:0.014759:0.013123:0.013143:0.006523:0.011738:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.014759:0.013123:0.005715:0.012604:0.012450:0.012508:0.007466:0.007466:0.012508:0.007466:0.005330
such as oncogenesis, tumour angiogene-:@0.524242:0.141464:0.915151:0.141464:0.915151:0.125709:0.524242:0.125709:0.007466:0.011699:0.012450:0.011738:0.006754:0.013143:0.007466:0.006754:0.012604:0.011738:0.012450:0.012604:0.012937:0.012508:0.011738:0.012508:0.007466:0.003848:0.007466:0.005330:0.006754:0.006523:0.011699:0.018049:0.012604:0.011699:0.005778:0.006754:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.012515:0.006388
sis, metastasis and tumour immunity.  Re-:@0.524242:0.156956:0.915155:0.156984:0.915155:0.141228:0.524242:0.141200:0.007466:0.003848:0.007466:0.005330:0.005523:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.003848:0.007466:0.005534:0.013143:0.011738:0.013181:0.005523:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005505:0.003848:0.018049:0.018049:0.011699:0.011738:0.003848:0.006523:0.010314:0.005330:0.018655:0.005523:0.011680:0.012508:0.340355
125:@0.860405:0.151365:0.879050:0.151365:0.879050:0.142179:0.860405:0.142179:0.006215:0.006215:0.006215
gorafenib is indicated for metastatic colo-:@0.524245:0.172475:0.915155:0.172475:0.915155:0.156719:0.524245:0.156719:0.012950:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.004984:0.003848:0.007466:0.004984:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.004984:0.006042:0.012604:0.005792:0.004984:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.004984:0.012450:0.012604:0.003848:0.012604:0.006388
rectal cancer  previously treated  with or :@0.524245:0.187967:0.920506:0.187967:0.920506:0.172211:0.524245:0.172211:0.005713:0.012508:0.012450:0.006523:0.013143:0.003848:0.010064:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.004718:0.013123:0.005713:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.010064:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.004720:0.015990:0.003848:0.006523:0.011738:0.010064:0.012604:0.005792:0.005330
contra-indicated :@0.524245:0.203458:0.688633:0.203458:0.688633:0.187702:0.524245:0.187702:0.012450:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
for :@0.709717:0.203458:0.739485:0.203458:0.739485:0.187702:0.709717:0.187702:0.006042:0.012604:0.005792:0.005330
fluoropyrimidine-:@0.760567:0.203458:0.915149:0.203458:0.915149:0.187702:0.760567:0.187702:0.004666:0.004666:0.011699:0.012604:0.005703:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.006388
based chemotherapy, oxaliplatin- and iri-:@0.524245:0.218949:0.915155:0.218949:0.915155:0.203194:0.524245:0.203194:0.013123:0.013143:0.007466:0.012508:0.013181:0.006619:0.012450:0.011738:0.012508:0.018049:0.012604:0.006514:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006602:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.006388:0.006619:0.013143:0.011738:0.013181:0.006608:0.003848:0.005792:0.003848:0.006388
notecan-based  chemotherapy,  an anti-:@0.524245:0.234441:0.915161:0.234441:0.915161:0.218685:0.524245:0.218685:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330:0.005357:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.005347:0.013143:0.011738:0.010699:0.013143:0.011738:0.006523:0.003848:0.006388
VEGF therapy,  and,  if RAS  wild-type, an :@0.524245:0.249932:0.920504:0.249932:0.920504:0.234176:0.524245:0.234176:0.013508:0.010314:0.016779:0.009333:0.009640:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.004299:0.013143:0.011738:0.013181:0.005330:0.005330:0.004299:0.003848:0.006042:0.009640:0.011680:0.014239:0.009583:0.005330:0.004295:0.015990:0.003848:0.003848:0.013181:0.006388:0.006523:0.010314:0.013123:0.012508:0.005330:0.009640:0.013143:0.011738:0.005330
anti-EGFR therapy.  Regorafenib is fur-:@0.524245:0.265424:0.915155:0.265463:0.915155:0.249707:0.524245:0.249668:0.013143:0.011738:0.006523:0.003848:0.006388:0.010314:0.016779:0.009333:0.011680:0.013277:0.006523:0.011738:0.012508:0.005780:0.013143:0.013123:0.010314:0.005330:0.012434:0.013277:0.011680:0.012508:0.012950:0.012604:0.005792:0.013131:0.006042:0.012508:0.011738:0.003848:0.013123:0.013277:0.003848:0.007466:0.013277:0.006042:0.011699:0.005792:0.182568
13:@0.705728:0.259844:0.718158:0.259844:0.718158:0.250658:0.705728:0.250658:0.006215:0.006215
thermore  indicated  for  the  treatment  of :@0.524238:0.280954:0.920479:0.280954:0.920479:0.265198:0.524238:0.265198:0.006523:0.011738:0.012508:0.006315:0.018049:0.012604:0.005709:0.012508:0.005330:0.004166:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.004166:0.006042:0.012604:0.005792:0.005330:0.004158:0.006523:0.011738:0.012508:0.005330:0.004160:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004156:0.012604:0.006042:0.005330
GIST previously treated with two tyrosine :@0.524238:0.296446:0.920481:0.296446:0.920481:0.280690:0.524238:0.280690:0.016779:0.004349:0.009583:0.008197:0.009236:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010325:0.009236:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.009236:0.015990:0.003848:0.006523:0.011738:0.009236:0.006523:0.015990:0.012604:0.009236:0.006523:0.010314:0.005711:0.012604:0.007466:0.003848:0.011738:0.012508:0.005330
kinase inhibitors and hepatocellular carci-:@0.524238:0.311937:0.915147:0.311937:0.915147:0.296181:0.524238:0.296181:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005811:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005811:0.013143:0.011738:0.013181:0.005811:0.011738:0.012508:0.013123:0.013143:0.006523:0.012604:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005811:0.012450:0.013143:0.005657:0.012450:0.003848:0.006388
noma (HCC) which has been previously :@0.524238:0.327428:0.920458:0.327428:0.920458:0.311672:0.524238:0.311672:0.011738:0.012604:0.018049:0.013143:0.009390:0.007100:0.013143:0.015644:0.015644:0.007100:0.009390:0.015990:0.011738:0.003848:0.012450:0.011738:0.009390:0.011738:0.013143:0.007466:0.009390:0.013123:0.012508:0.012508:0.011738:0.009390:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
treated with sorafenib.:@0.524238:0.342920:0.734686:0.342920:0.734686:0.327164:0.524238:0.327164:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330
Vemurafenib inhibits some mutated :@0.542422:0.358411:0.920479:0.358411:0.920479:0.342655:0.542422:0.342655:0.011374:0.012315:0.017857:0.011507:0.005600:0.012950:0.005850:0.012315:0.011545:0.003656:0.012931:0.021301:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.007274:0.021301:0.007274:0.012411:0.017857:0.012315:0.021301:0.017857:0.011507:0.006331:0.012950:0.006331:0.012315:0.013181:0.005330
forms of BRAF serine threonine kinase, in-:@0.524238:0.373902:0.915178:0.373902:0.915178:0.358146:0.524238:0.358146:0.005850:0.012411:0.006133:0.017857:0.007274:0.008967:0.012411:0.005850:0.008967:0.010853:0.011488:0.014047:0.009140:0.008967:0.007274:0.012315:0.005600:0.003656:0.011545:0.012315:0.008967:0.006331:0.011545:0.005521:0.012315:0.012411:0.011545:0.003656:0.011545:0.012315:0.008967:0.009467:0.003656:0.011545:0.012950:0.007274:0.012315:0.005138:0.008967:0.003656:0.011545:0.006388
cluding BRAF V600E, and has been shown :@0.524238:0.389394:0.920514:0.389394:0.920514:0.373638:0.524238:0.373638:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012758:0.006658:0.010853:0.011488:0.014047:0.009140:0.006658:0.013316:0.010468:0.010468:0.010468:0.010122:0.005138:0.006658:0.012950:0.011545:0.012989:0.006658:0.011545:0.012950:0.007274:0.006658:0.012931:0.012315:0.012315:0.011545:0.006658:0.007274:0.011545:0.012411:0.015798:0.011736:0.005330
to inhibit CRAF, ARAF, wild-type BRAF, :@0.524238:0.404885:0.920520:0.404885:0.920520:0.389129:0.524238:0.389129:0.006331:0.012411:0.016395:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.016395:0.015452:0.011488:0.014047:0.006789:0.005138:0.016395:0.014047:0.011488:0.014047:0.006789:0.005138:0.016395:0.015798:0.003656:0.003656:0.012989:0.006196:0.006331:0.010122:0.012931:0.012315:0.016395:0.010853:0.011488:0.014047:0.006789:0.005326:0.005330
SRMS, ACK1, MAP4K5, and FGR :@0.524238:0.420376:0.826690:0.420376:0.826690:0.404621:0.524238:0.404621:0.009390:0.011488:0.017491:0.009390:0.005138:0.008313:0.014047:0.015452:0.011180:0.010468:0.005138:0.008313:0.017491:0.014047:0.011199:0.010468:0.011180:0.010468:0.005138:0.008313:0.012950:0.011545:0.012989:0.008313:0.009140:0.016587:0.011488:0.005330
in vitro:@0.829672:0.420376:0.891845:0.420376:0.891845:0.404621:0.829672:0.404621:0.003656:0.011545:0.008313:0.010468:0.003656:0.006331:0.005600:0.012604
.  :@0.891652:0.420376:0.920481:0.420433:0.920481:0.404677:0.891652:0.404621:0.005330:0.018168:-0.049227
131:@0.896723:0.414814:0.915144:0.414814:0.915144:0.405628:0.896723:0.405628:0.006103:0.006103:0.006215
Some mutations in the BRAF gene including :@0.524241:0.435924:0.920537:0.435924:0.920537:0.420168:0.524241:0.420168:0.009390:0.012411:0.017857:0.012315:0.004253:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.007274:0.004253:0.003656:0.011545:0.004253:0.006331:0.011545:0.012315:0.004253:0.010853:0.011488:0.014047:0.009140:0.004253:0.012758:0.012315:0.011545:0.012315:0.004253:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012948:0.005330
V600E result in constitutively activated BRAF :@0.524241:0.451416:0.920438:0.451416:0.920438:0.435660:0.524241:0.435660:0.013316:0.010468:0.010468:0.010468:0.010122:0.004079:0.005521:0.012315:0.007274:0.011507:0.003656:0.006331:0.004079:0.003656:0.011545:0.004079:0.012257:0.012411:0.011545:0.007274:0.006331:0.003656:0.006331:0.011507:0.006331:0.003656:0.010468:0.012315:0.003656:0.010122:0.004079:0.012950:0.012257:0.006331:0.003656:0.010468:0.012950:0.006331:0.012315:0.012989:0.004079:0.010853:0.011488:0.014047:0.009331:0.005330
proteins, which can cause cell proliferation :@0.524241:0.466907:0.920473:0.466907:0.920473:0.451151:0.524241:0.451151:0.012931:0.005521:0.012411:0.006331:0.012315:0.003656:0.011545:0.007274:0.005138:0.005003:0.015798:0.011545:0.003656:0.012257:0.011545:0.005003:0.012257:0.012950:0.011545:0.005003:0.012257:0.012950:0.011507:0.007274:0.012315:0.005003:0.012257:0.012315:0.003656:0.003656:0.005003:0.012931:0.005521:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.012411:0.011734:0.005330
in the absence of growth factors that :@0.524241:0.482398:0.920475:0.482398:0.920475:0.466642:0.524241:0.466642:0.003656:0.011545:0.013547:0.006331:0.011545:0.012315:0.013547:0.012950:0.012931:0.007274:0.012315:0.011545:0.012257:0.012315:0.013547:0.012411:0.005850:0.013547:0.012758:0.005519:0.012411:0.015798:0.006331:0.011545:0.013547:0.005850:0.012950:0.012257:0.006331:0.012411:0.005600:0.007274:0.013547:0.006331:0.011545:0.012950:0.006521:0.005330
would normally be required for prolifera-:@0.524241:0.497890:0.915137:0.497890:0.915137:0.482134:0.524241:0.482134:0.015798:0.012411:0.011507:0.003656:0.012989:0.009814:0.011545:0.012411:0.006133:0.017857:0.012950:0.003656:0.003656:0.010122:0.009814:0.012931:0.012315:0.009814:0.005521:0.012315:0.012931:0.011507:0.003656:0.005521:0.012315:0.012989:0.009814:0.005850:0.012411:0.005600:0.009814:0.012931:0.005519:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006388
tion. Vemurafenib is indicated for the treat-:@0.524241:0.513381:0.915208:0.513381:0.915208:0.497625:0.524241:0.497625:0.006331:0.003656:0.012411:0.011545:0.005138:0.005080:0.011374:0.012315:0.017857:0.011507:0.005600:0.012950:0.005850:0.012315:0.011545:0.003656:0.012931:0.005080:0.003656:0.007274:0.005080:0.003656:0.011545:0.012989:0.003656:0.012257:0.012950:0.006331:0.012315:0.012989:0.005080:0.005850:0.012411:0.005600:0.005080:0.006331:0.011545:0.012315:0.005080:0.006331:0.005521:0.012315:0.012950:0.006331:0.006388
ment of unresectable or metastatic mela-:@0.524241:0.528872:0.915147:0.528872:0.915147:0.513116:0.524241:0.513116:0.017857:0.012315:0.011545:0.006331:0.006850:0.012411:0.005850:0.006850:0.011507:0.011545:0.005519:0.012315:0.007274:0.012315:0.012257:0.006331:0.012950:0.012931:0.003656:0.012315:0.006850:0.012411:0.005600:0.006850:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.006850:0.017857:0.012315:0.003656:0.012950:0.006388
noma with BRAF V600E mutation, Erdheim :@0.524241:0.544364:0.920479:0.544364:0.920479:0.528608:0.524241:0.528608:0.011545:0.012411:0.017857:0.012950:0.007312:0.015798:0.003656:0.006331:0.011545:0.007312:0.010853:0.011488:0.014047:0.009140:0.007312:0.013316:0.010468:0.010468:0.010468:0.010122:0.007312:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.007312:0.010122:0.005482:0.012989:0.011545:0.012315:0.003656:0.018049:0.005330
Chester Disease with BRAF V600 mutation.:@0.524241:0.559855:0.906164:0.559855:0.906164:0.544099:0.524241:0.544099:0.015452:0.011545:0.012315:0.007274:0.006331:0.012315:0.005600:0.005138:0.014124:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.005138:0.015798:0.003656:0.006331:0.011545:0.005138:0.010853:0.011488:0.014047:0.009140:0.005138:0.013316:0.010468:0.010468:0.010468:0.005138:0.017857:0.011507:0.006331:0.012950:0.006331:0.003656:0.012411:0.011545:0.005330
INTERFERONS:@0.524242:0.591958:0.657228:0.591958:0.657228:0.574143:0.524242:0.574143:0.005987:0.015822:0.008980:0.011118:0.012401:0.010263:0.011118:0.012401:0.017960:0.015822:0.011118
Interferons (IFNs) are cytokines produced :@0.524242:0.608602:0.920512:0.608602:0.920512:0.592846:0.524242:0.592846:0.004349:0.011738:0.006523:0.012508:0.006702:0.006042:0.012508:0.005711:0.012604:0.011738:0.007466:0.007624:0.007100:0.004349:0.009333:0.014239:0.007466:0.007100:0.007639:0.013143:0.005715:0.012508:0.007626:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.007466:0.007639:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.012508:0.013181:0.005330
naturally by host cells in the presence of a :@0.524242:0.624093:0.920476:0.624093:0.920476:0.608337:0.524242:0.608337:0.011738:0.013143:0.006523:0.011699:0.005792:0.013143:0.003848:0.003848:0.010314:0.005349:0.013123:0.010314:0.005349:0.011738:0.012604:0.007466:0.006523:0.005349:0.012450:0.012508:0.003848:0.003848:0.007466:0.005361:0.003848:0.011738:0.005349:0.006523:0.011738:0.012508:0.005349:0.013123:0.005717:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005349:0.012604:0.006042:0.005349:0.013143:0.005330
pathogen such as a tumour cell, bacteria, :@0.524242:0.639584:0.920499:0.639584:0.920499:0.623829:0.524242:0.623829:0.013123:0.013143:0.006523:0.011738:0.012604:0.012950:0.012508:0.011738:0.004868:0.007466:0.011699:0.012450:0.011738:0.004888:0.013143:0.007466:0.004888:0.013143:0.004888:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004866:0.012450:0.012508:0.003848:0.003848:0.005330:0.004888:0.013123:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.013143:0.005330:0.005330
virus or parasite. IFNs bind to specific cell-:@0.524242:0.655076:0.915146:0.655076:0.915146:0.639320:0.524242:0.639320:0.010660:0.003848:0.005792:0.011699:0.007466:0.006506:0.012604:0.005792:0.006492:0.013123:0.013143:0.005792:0.013143:0.007466:0.003848:0.006523:0.012508:0.005330:0.006502:0.004349:0.009333:0.014239:0.007466:0.006498:0.013123:0.003848:0.011738:0.013181:0.006506:0.006523:0.012604:0.006494:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.006504:0.012450:0.012508:0.003848:0.003848:0.006388
membrane receptors and initiate a com-:@0.524242:0.670567:0.915150:0.670567:0.915150:0.654811:0.524242:0.654811:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.006927:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007466:0.006927:0.013143:0.011738:0.013181:0.006927:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.012508:0.006927:0.013143:0.006927:0.012450:0.012604:0.018049:0.006388
plex sequence of events, facilitating com-:@0.524242:0.686059:0.915123:0.686059:0.915123:0.670303:0.524242:0.670303:0.013123:0.003848:0.012508:0.009236:0.005080:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.012450:0.012498:0.005080:0.012604:0.006042:0.005080:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.005080:0.006042:0.013143:0.012450:0.003848:0.003848:0.003848:0.006523:0.013143:0.006523:0.003848:0.011738:0.012950:0.005080:0.012450:0.012604:0.018049:0.006388
munication:@0.524242:0.701550:0.629883:0.701550:0.629883:0.685794:0.524242:0.685794:0.018049:0.011699:0.011738:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738
between:@0.656226:0.701550:0.741123:0.701550:0.741123:0.685794:0.656226:0.685794:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738
immune:@0.767466:0.701550:0.843358:0.701550:0.843358:0.685794:0.767466:0.685794:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508
cells,:@0.869701:0.701550:0.915151:0.701550:0.915151:0.685794:0.869701:0.685794:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
enabling them to destroy a pathogen.:@0.524242:0.717041:0.893425:0.717041:0.893425:0.701285:0.524242:0.701285:0.012508:0.011738:0.013143:0.013123:0.003848:0.003848:0.011738:0.012950:0.007447:0.006523:0.011738:0.012508:0.018049:0.007447:0.006523:0.012604:0.007447:0.013181:0.012508:0.007466:0.006523:0.005713:0.012604:0.010314:0.007447:0.013143:0.007447:0.013123:0.013143:0.006523:0.011738:0.012604:0.012950:0.012508:0.011738:0.005330
4,26:@0.893393:0.711462:0.915146:0.711462:0.915146:0.702276:0.893393:0.702276:0.006215:0.003107:0.006215:0.006215
 :@0.915151:0.717081:0.920481:0.717081:0.920481:0.701325:0.915151:0.701325:0.005330
The  immunomodulating  activities of  IFNs :@0.524241:0.732572:0.920479:0.732572:0.920479:0.716816:0.524241:0.716816:0.008197:0.011738:0.012508:0.005330:0.004674:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.018049:0.012590:0.013181:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.005330:0.004686:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.003848:0.012508:0.007466:0.010025:0.012604:0.006042:0.005330:0.004680:0.004349:0.009333:0.014239:0.007466:0.005330
include the direct antiproliferative effects :@0.524241:0.748063:0.920479:0.748063:0.920479:0.732308:0.524241:0.732308:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006908:0.006523:0.011738:0.012508:0.006908:0.013181:0.003848:0.005717:0.012508:0.012450:0.006523:0.006908:0.013143:0.011738:0.006523:0.003848:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.006908:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330
on tumour cells,  enhancement  of the :@0.524241:0.763555:0.920500:0.763555:0.920500:0.747799:0.524241:0.747799:0.012604:0.011738:0.014143:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.014143:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.005330:0.008826:0.012508:0.011738:0.011738:0.013143:0.011738:0.012450:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.008800:0.012604:0.006042:0.014143:0.006523:0.011738:0.012508:0.005330
phagocytic activity of macrophages, up-:@0.524241:0.779046:0.915160:0.779046:0.915160:0.763290:0.524241:0.763290:0.013123:0.011738:0.013143:0.012950:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.006600:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.006600:0.012604:0.006042:0.006591:0.018049:0.013143:0.012450:0.005715:0.012604:0.013123:0.011738:0.013143:0.012950:0.012508:0.007466:0.005330:0.006600:0.011699:0.013123:0.006388
regulating tumour antigen presentation to :@0.524241:0.794538:0.920498:0.794538:0.920498:0.778782:0.524241:0.778782:0.005713:0.012508:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.005157:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005157:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.005155:0.013123:0.005717:0.012508:0.007466:0.012508:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005157:0.006523:0.012604:0.005330
cytotoxic T-lymphocytes and activation of :@0.524241:0.810029:0.920479:0.810029:0.920479:0.794273:0.524241:0.794273:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.004905:0.008197:0.006388:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.007466:0.004911:0.013143:0.011738:0.013181:0.004915:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.003848:0.012604:0.011738:0.004915:0.012604:0.006042:0.005330
natural killer cells.:@0.524241:0.825520:0.685743:0.825520:0.685743:0.809764:0.524241:0.809764:0.011738:0.013143:0.006523:0.011699:0.005792:0.013143:0.003848:0.005330:0.009660:0.003848:0.003848:0.003848:0.012508:0.005792:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
4,26,39:@0.685745:0.819941:0.723034:0.819941:0.723034:0.810755:0.685745:0.810755:0.006215:0.003107:0.006215:0.006215:0.003107:0.006215:0.006215
 :@0.723042:0.825560:0.728372:0.825560:0.728372:0.809804:0.723042:0.809804:0.005330
Interferon-alpha and beta:@0.524242:0.857612:0.793635:0.857612:0.793635:0.839797:0.524242:0.839797:0.005987:0.012828:0.006414:0.013683:0.006842:0.005987:0.013683:0.006842:0.013683:0.012828:0.008980:0.014111:0.005131:0.014111:0.012828:0.014111:0.005987:0.014111:0.012828:0.014111:0.005987:0.014111:0.013683:0.006414:0.014111
Interferon-alpha (INF- ) and interferon-be-:@0.524242:0.874256:0.915163:0.874256:0.915163:0.858500:0.524242:0.858500:0.004156:0.011545:0.006331:0.012315:0.006515:0.005850:0.012315:0.005519:0.012411:0.011545:0.006196:0.012950:0.003656:0.012931:0.011545:0.012950:0.007216:0.006908:0.004156:0.014047:0.009140:0.006388:0.009671:0.006908:0.007216:0.012950:0.011545:0.012989:0.007216:0.003656:0.011545:0.006331:0.012315:0.006517:0.005850:0.012315:0.005521:0.012411:0.011545:0.006196:0.012931:0.012315:0.006388
α:@0.720637:0.876108:0.730701:0.876108:0.730701:0.858262:0.720637:0.858262:0.010064
ta (INF- ) are cytokines which form part of :@0.524242:0.889747:0.920487:0.889747:0.920487:0.873991:0.524242:0.873991:0.006331:0.012950:0.006454:0.006908:0.004156:0.014047:0.009140:0.006388:0.009421:0.006908:0.006456:0.012950:0.005521:0.012315:0.006456:0.012257:0.010122:0.006331:0.012411:0.009467:0.003656:0.011545:0.012315:0.007274:0.006454:0.015798:0.011545:0.003656:0.012257:0.011545:0.006456:0.005850:0.012411:0.006131:0.017857:0.006456:0.012931:0.012950:0.005600:0.006331:0.006454:0.012411:0.006042:0.005330
β:@0.590424:0.891599:0.600238:0.891599:0.600238:0.873753:0.590424:0.873753:0.009814
a large subclass of interferons better known :@0.524242:0.905238:0.920512:0.905238:0.920512:0.889482:0.524242:0.889482:0.012950:0.004214:0.003656:0.012950:0.005615:0.012758:0.012315:0.004204:0.007274:0.011507:0.012931:0.012257:0.003656:0.012950:0.007274:0.007274:0.004214:0.012411:0.005850:0.004204:0.003656:0.011545:0.006331:0.012315:0.006515:0.005850:0.012315:0.005521:0.012411:0.011545:0.007274:0.004214:0.012931:0.012315:0.006331:0.006331:0.012315:0.005600:0.004204:0.009467:0.011545:0.012411:0.015798:0.011734:0.005330
as type I IFNs.:@0.524242:0.920730:0.647874:0.920730:0.647874:0.904974:0.524242:0.904974:0.012950:0.007274:0.005869:0.006331:0.010122:0.012931:0.012315:0.005869:0.004156:0.005869:0.004156:0.009140:0.014047:0.007274:0.005330
41,42:@0.647690:0.915128:0.675208:0.915128:0.675208:0.905942:0.647690:0.905942:0.006103:0.006103:0.002995:0.006103:0.006215
 The host cells, in response :@0.675103:0.920747:0.920478:0.920747:0.920478:0.904991:0.675103:0.904991:0.005869:0.008005:0.011545:0.012315:0.005869:0.011545:0.012411:0.007274:0.006331:0.005869:0.012257:0.012315:0.003656:0.003656:0.007274:0.005138:0.005869:0.003656:0.011545:0.005869:0.005521:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.012506:0.005330
to a pathogen, produce cytokines such as :@0.524243:0.936238:0.920521:0.936238:0.920521:0.920482:0.524243:0.920482:0.006331:0.012411:0.005503:0.012950:0.005503:0.012931:0.012950:0.006331:0.011545:0.012411:0.012758:0.012315:0.011545:0.005138:0.005503:0.012931:0.005519:0.012411:0.012989:0.011507:0.012257:0.012315:0.005503:0.012257:0.010122:0.006331:0.012411:0.009467:0.003656:0.011545:0.012315:0.007274:0.005503:0.007274:0.011507:0.012257:0.011545:0.005503:0.012950:0.007470:0.005330
Biologicals:@0.795172:0.038601:0.914528:0.038601:0.914528:0.019343:0.795172:0.019343:0.013500:0.004704:0.015405:0.004704:0.015405:0.015828:0.004704:0.015216:0.016063:0.004704:0.009125